XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology
| Autor: | Ozgur Tanriverdi, Serkan Menekse, Faysal Dane, Mukremin Uysal, Metin Ozkan, Halit Karaca, Mehmet Besiroglu, Ibrahim Vedat Bayoglu, Ayse Ocak Duran, Dogan Yazilitas, Alper Sevinc, Ilhan Hacibekiroglu, Erkan Arpaci, Aykut Bahceci, Mevlude Inanc, Heves Surmeli Yapici, Asude Aksoy |
|---|---|
| Přispěvatelé: | MÜ, [Duran, Ayse Ocak -- Karaca, Halit -- Ozkan, Metin] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey -- [Besiroglu, Mehmet -- Dane, Faysal] Marmara Univ, Dept Med Oncol, Istanbul, Turkey -- [Bayoglu, Ibrahim Vedat] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey -- [Menekse, Serkan] Celal Bayar Univ, Dept Med Oncol, Manisa, Turkey -- [Yapici, Heves Surmeli] Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Yazilitas, Dogan] Konya Training & Res Hosp, Dept Med Oncol, Konya, Turkey -- [Bahceci, Aykut] Cumhuriyet Univ, Dept Med Oncol, Sivas, Turkey -- [Uysal, Mukremin] Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey -- [Sevinc, Alper] Gaziantep Univ, Dept Med Oncol, Gaziantep, Turkey -- [Hacibekiroglu, Ilhan] Trakya Univ, Dept Med Oncol, Edirne, Turkey -- [Aksoy, Asude] Firat Univ, Dept Med Oncol, TR-23169 Elazig, Turkey -- [Tanriverdi, Ozgur] Mugla Univ, Dept Med Oncol, Mugla, Turkey -- [Arpaci, Erkan] Sakarya Training & Res Hosp, Dept Med Oncol, Sakarya, Turkey -- [Inanc, Mevlude] Kayseri Educ & Res Hosp, Dept Med Oncol, Kayseri, Turkey, aksoy, asude -- 0000-0002-5609-9658 |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Bevacizumab Oxaloacetates Epidemiology Colorectal cancer medicine.medical_treatment Leucovorin Angiogenesis Inhibitors Bone Neoplasms Comparison Antibodies Monoclonal Humanized Deoxycytidine Capecitabine XELOX Plus Bevacizumab Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis FOLFIRI Plus Bevacizumab Aged Retrospective Studies Chemotherapy business.industry Carcinoma Liver Neoplasms Public Health Environmental and Occupational Health Retrospective cohort study Middle Aged medicine.disease Treatment Outcome Monoclonal Colonic Neoplasms FOLFIRI Camptothecin Female Fluorouracil business Metastatic Colorectal Cancer Progressive disease medicine.drug |
| Popis: | WOS: 000351058400056 PubMed ID: 25556478 Background: XELOX plus bevacizumab (XELOX-Bev) and FOLFIRI plus Bevacizumab (FOLFIRI - Bev) treatments are an effective strategies patients with metastatic colorectal cancer (mCRC). The aim of this study was to compare efficacy of first-line XELOX-Bev treatment vs FOLFIRI-Bev treatment for mCRC. Materials and Methods: A total of 409 patients with mCRC who received chemotherapy were included and divided into 2 groups. Group 1 (n=298) received XELOX-Bev and Group 2 (n=111) FOLFIRI-Bev. Comparisons were made in terms of overall (OS) and progression-free (PFS) survival, response rate (RR), and grade 3-4 toxicity. Results: Median follow-up was 11 months in Group 1 and 15 months for Group 2. Complete remission was observed in 29 (9.7%) and 2 (1.8%) patients, partial remission in 139 (46.6%) and 27 (24.5%), stable disease in 88 (29.5%) and 49 (44.1%) and progressive disease in 42 (14.1%) and 33 (30.0%) patients in Group 1 and 2, respectively. Median OS was 25 months (range 2-57 months, 95% CI; 22.2-27.7) for Group 1 and 20 months (range 1-67 months, 95% CI; 16.8-23.1) for Group 2 (p=0.036). Median PFS was 9.6 months (range 2-36 months, 95% CI; 8.8-10.4) for Group 1 and 9 months (range 1-44 months, 95% CI; 7.4-10.5) for Group 2 (p=0.019). Objective RR was 56.4% in Group 1 and 26.1% in Group 2 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|